Brief: Daewoong Pharma Begins Phase 2 trial for DWN12088
24/06/2022 14:32
June 24 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL BEGINS MULTINATIONAL PHASE 2
CLINICAL
TRIAL FOR DWN12088, A NEW DRUG FOR IDIOPATHIC PULMONARY FIBROSIS
Source text for Eikon: ID:nPn1Y9TGha
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier